Asthma and chronic obstruction pulmonary disease: A family of diseases with overlapping clinical manifestations

Aim. To evaluate the efficiency of decimeter wave therapy and halotherapy, which were additionally added to basic therapy, in patients with chronic obstructive pulmonary disease (COPD) concurrent with hypertension at the inpatient stage. Subject and methods. 36 patients aged 20 to 75 years with Stages I—II COPD concurrent with Stages I—II, first-second grade hypertension were examined and treated. The clinical examination included collection of complaints and medical history data, clinical laboratory and instrumental (electrocardiography, spirography) studies, and health-related quality of life (using the SF-36 questionnaire). The patients were randomized into two groups: a study group and a comparison group. The study group patients received decimeter wave therapy and halotherapy in addition to basic drug treatment; the comparison patients had basic drug therapy. Results. Pre- and postoperative comparative analysis of the major clinical manifestations of comorbidities revealed more pronounced positive changes with the lower rate of clinical manifestations in the study group. It was also observed to have a more marked reduction in blood pressure (BP) with its goal levels achieved. The mean pulse BP decreased by 28% in the study group (p=0.000005) and did not statistically reduced in the comparison group. In the study group patients, the integral quality-of-life indicator after a package of medical rehabilitation measures became statistically significantly higher by 35%. This indicator in the comparison group was statistically significantly unchanged. Conclusion. The directionality of the proposed rehabilitation complex towards the common pathogenetic components of the development and progression of COPD and hypertension, as well as the high efficiency of the complex justify its appropriate inclusion in the combination treatment and rehabilitation of this category of patients.

Download Full-text

Gender Differences in the Clinical Manifestations and Prognosis of Patients Hospitalized with Acute Exacerbations of Chronic Obstructive Pulmonary Disease

West Indian Medical Journal ◽

10.7727/wimjopen.2013.250 ◽

2014 ◽

Vol 1 ◽

pp. 1-5

Author(s):

S Yu ◽

Q Fang ◽

Y Ma ◽

R Li ◽

L Guo

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Gender Differences ◽

Pulmonary Disease ◽

Clinical Manifestations ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Acute Exacerbations

Download Full-text

Cardiopulmonary syndrome and adrenoreactivity of an organism

Kazan medical journal ◽

10.17750/kmj2016-864 ◽

2016 ◽

Vol 97 (6) ◽

pp. 864-869 ◽

Cited By ~ 2

Author(s):

V M Gazizyanova ◽

O V Bulashova ◽

A A Nasybullina ◽

Z A Shaykhutdinova ◽

A A Podol’skaya

Keyword(s):

Heart Failure ◽

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Clinical Features ◽

Clinical Manifestations ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Heart Failure Patients ◽

Increased Activity

Aim. To study β-adrenoreactivity of the cell membrane in patients with different variants of heart failure in association with chronic obstructive pulmonary disease.Methods. 120 heart failure patients including 68 of them who suffer from concominant chronic obstructive pulmonary disease were evaluated. Assessment of clinical features of heart failure, patients’ quality of life and study of β-adrenoreactivity were performed.Results. Adrenoreactivity of an organism in heart failure and concominant chronic obstructive pulmonary disease was 2 times higher and was 55.4±18.8 U and in heart failure only it was 29.4±8.5 U. Intensification of β-adrenoreactivity was found to be proportional to worsening of clinical features of chronic heart failure in all patients that was more prominent in patients with pulmonary disease. Responders with heart failure in association with chronic obstructive pulmonary disease had higher values of β-adrenoreactivity of cell membranes more frequently.Conclusion. The results of our investigation confirm increased activity of sympathetic system in heart failure and concominant chronic obstructive pulmonary disease that worsens clinical manifestations of heart failure.

Download Full-text

Chronic obstructive pulmonary disease and concurrent cardiovascular conditions: safety of tiotropium/olodaterol combination

Russian Pulmonology ◽

10.18093/0869-0189-2021-31-4-511-516 ◽

2021 ◽

Vol 31 (4) ◽

pp. 511-516

Author(s):

A. G. Romanovskikh ◽

A. I. Sinopal’nikov ◽

Yu. G. Belotserkovskaya ◽

I. P. Smirnov

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Safety Profile ◽

Clinical Manifestations ◽

Fixed Dose ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Anticholinergic Medications ◽

Negative Effect ◽

Long Acting

One of the important features of the chronic obstructive pulmonary disease is the presence of concomitant chronic diseases in most of patients. And cardiovascular conditions occupy a special place among these comorbidities. The most common diseases associated with COPD are hypertension, coronary heart disease, and heart failure. They aggravate the clinical manifestations of the disease and have negative effect on the prognosis. In addition, concomitant cardiovascular conditions determine the need for a thorough safety assessment of the ongoing pharmacotherapy for COPD. Core of the treatment is bronchodilators. The priority pharmacological strategy is the use of fixed-dose combinations of long-acting β2 -agonists and long-acting anticholinergic medications.The purpose of this review was to evaluate the safety profile of tiotropium/olodaterol in COPD.Methods. This article presents the data obtained from studies of the safety of the use of tiotropium/olodaterol in patients with COPD and concomitant cardiovascular conditions.Results. The studies showed no increase in the risk of cardiovascular events when using this combination in patients of this category.Conclusion. А good safety profile of tiotropium/olodaterol was confirmed in patients with COPD and concomitant cardiovascular conditions.

Download Full-text

Comparison of the Spectrum of Radiologic and Clinical Manifestations of Pulmonary Disease Caused by Mycobacterium avium Complex and Mycobacterium xenopi

Canadian Association of Radiologists Journal ◽

10.1016/j.carj.2013.05.006 ◽

2014 ◽

Vol 65 (3) ◽

pp. 207-213 ◽

Cited By ~ 18

Author(s):

Maria C. Carrillo ◽

Demetris Patsios ◽

Ute Wagnetz ◽

Frances Jamieson ◽

Theodore K. Marras

Keyword(s):

Computed Tomography ◽

Lung Disease ◽

Pulmonary Disease ◽

Clinical Data ◽

Mycobacterium Avium ◽

Mycobacterium Avium Complex ◽

Clinical Manifestations ◽

Ground Glass ◽

Mycobacterium Xenopi ◽

Significant Difference

Aim Mycobacterium xenopi is described with upper lobe cavitation (“fibrocavitary” pattern), whereas the Mycobacterium avium complex (MAC) is described with bronchiectasis and centrilobular nodules (“nodular bronchiectasis”). We retrospectively described and compared computed tomography (CT) chest manifestations of disease caused by MAC and M xenopi. Materials and Methods We reviewed patients who had either MAC or M xenopi lung disease and who had CTs between January 2002 and December 2003. Clinical data were recorded, and the patterns on chest CTs were categorized as “fibrocavitary,” “nodular bronchiectatic,” and “unclassified.” Results There were 74 patients; 50 with MAC and 24 with M xenopi. The patients with MAC were older (mean 69 vs 58 years; P = .007). Patients with M xenopi more often had emphysema (50% vs 20%; P = .02), cavities (46% vs 16%; P = .01), and nodules ≤5 mm (88% vs 58%; P = .02). M xenopi cases more commonly had a fibrocavitary radiologic pattern (33% vs 18%), with no statistically significant difference ( P = .24). MA C was more often associated with a nodular bronchiectatic pattern (68% MAC vs 4% M xenopi; P < .0001). Sixty-three percent of patients with M xenopi had a pattern that was predominantly randomly distributed nodules (11/15 [73%]) or consolidation and/or ground-glass opacities (4/15 [27%]). Conclusion Compared with MAC, patients with M xenopi infection develop more cavities and more nodules, and they less often have a predominant nodular bronchiectatic pattern. Although a predominantly cavitary pattern appears to be more common with M xenopi, the majority of patients with M xenopi had CT patterns of random nodules or consolidation and/or ground-glass opacities rather than classically described findings.

Download Full-text

Imaging approaches to understand disease complexity: chronic obstructive pulmonary disease as a clinical model

Journal of Applied Physiology ◽

10.1152/japplphysiol.00143.2017 ◽

2018 ◽

Vol 124 (2) ◽

pp. 512-520 ◽

Cited By ~ 4

Author(s):

Karin J. C. Sanders ◽

Samuel Y. Ash ◽

George R. Washko ◽

Felix M. Mottaghy ◽

Annemie M. W. J. Schols

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Medical Imaging ◽

Pulmonary Disease ◽

Clinical Care ◽

Clinical Manifestations ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Clinical Model ◽

Imaging Research

The clinical manifestations of chronic obstructive pulmonary disease (COPD) reflect an aggregate of multiple pulmonary and extrapulmonary processes. It is increasingly clear that full assessment of these processes is essential to characterize disease burden and to tailor therapy. Medical imaging has advanced such that it is now possible to obtain in vivo insight in the presence and severity of lung disease-associated features. In this review, we have assembled data from multiple disciplines of medical imaging research to review the role of imaging in characterization of COPD. Topics include imaging of the lungs, body composition, and extrapulmonary tissue metabolism. The primary focus is on imaging modalities that are widely available in clinical care settings and that potentially contribute to describing COPD heterogeneity and enhance our insight in underlying pathophysiological processes and their structural and functional effects.

Download Full-text

A rare cause of secondary organising pneumonia

BMJ Case Reports ◽

10.1136/bcr-2021-241737 ◽

2021 ◽

Vol 14 (3) ◽

pp. e241737

Author(s):

Ana Luisa Fernandes ◽

Ana Ferro ◽

Joana dos Santos ◽

Bárbara Seabra

Keyword(s):

Bronchoalveolar Lavage ◽

Pulmonary Disease ◽

Mycobacterium Avium ◽

Lung Biopsy ◽

Clinical Manifestations ◽

Community Acquired Pneumonia ◽

Extensive Investigation ◽

Radiological Findings ◽

Ct Guided ◽

Respiratory Complaints

Non-tuberculous mycobacterial pulmonary disease may have different clinical manifestations. We report a case of a 64-year-old woman presenting with persistent respiratory complaints, fever and radiological findings. Initially, she was diagnosed with community-acquired pneumonia, but after being submitted to an extensive investigation, including CT-guided transthoracic lung biopsy, a diagnosis of organising pneumonia (OP) was established. The patient was treated with corticosteroids with no favourable response. Subsequently, Mycobacterium avium complex (MAC) was identified in bronchoalveolar lavage culture. The patient was diagnosed with OP secondary to MAC infection and specific antibiotic treatment was initiated. This case represents an infrequent association and illustrates how important it is to investigate primary causes of OP to obtain a satisfactory treatment response.

Download Full-text

Chronic obstructive pulmonary disease and anemia: clinical manifestations and therapeutic strategy

Clinical Medicine (Russian Journal) ◽

10.18821/0023-2149-2016-94-9-677-683 ◽

2016 ◽

Vol 94 (9) ◽

pp. 677-683

Author(s):

A. V. Budnevsky ◽

V. M. Provotorov ◽

Marina I. Ul’yanova

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Pulmonary Disease ◽

Clinical Manifestations ◽

Normocytic Anemia ◽

Chronic Obstructive ◽

Physical Endurance ◽

Shortness Of Breath ◽

Severe Condition ◽

Anemia Of Chronic Disease ◽

Obstructive Pulmonary Disease

Anemia refers to manifestations of systemic infl ammation in chronic obstructive pulmonary disease (COPD) and a factor aggravating the disease. Objective: to study gender characteristics of anemia in patients with COPD, to increase the effectiveness of treatment through the use of pharmacological agents erythropoietin and enteral iron. Materials and methods. The paper presents clinical data on 74 patients with stage II/III COPD and anemiaalong with results of the treatment of 49 patients who received standard therapy in addition to epoetin and Sorbiferdurules. Results. Patients with COPD much morefrequently presented with iron defi ciency anemia (IDA): 63 patients (85.1%) dominated by women (39 or 61.9% ) with men accounting only for 24 or 38.1% of the total. 11 patients (14.9%) had normochromic normocytic anemia with the parameters of anemia of chronic disease. The incidence of IDA in both groups correlated with age; it was largely a moderately severe condition that much more frequently occurred in women (24 out of 39 patients - 61,5%) than in men in whom the mild form of iron defi ciency prevailed (14 of 24 patients - 58,3%). Conclusion. The overall prevalence of anemia concomitant with COPD was estimated at 26.5%. It was documented in44 women (33.7%), i.e. in each third patient. It occurred less frequently in men (30 or 20,7%). The presence of anemia deteriorates conditions of the patients, especially female ones, who more often suffere from shortness of breath, impairedgeneral health status , fatigue, and depression; moreover, they more frequently need hospitalization. Correction of anemia with erythropoietin and iron preparations for the internal use can improve physical endurance of the patients, reduce cough intensity and shortness of breath,promote positive dynamics of physical tolerance for a prolonged period after the completion of antianemic therapy.

Download Full-text